Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      IDEXX Laboratories Announces Second Quarter Results

      IDEXX Laboratories, Inc. logo. (PRNewsFoto/IDEXX Laboratories, Inc.)

      News provided by

      IDEXX Laboratories, Inc.

      Aug 02, 2022, 06:30 ET

      Share this article

      Share this article


      • Achieves second quarter revenue growth of 4% reported and 6.5% organic, driven by CAG Diagnostics recurring revenue growth of 4% reported and 7% organic, building on high prior year growth
      • Solid demand for diagnostic services and strong IDEXX execution support record second quarter premium instrument placements, driving 15% growth in global premium installed base
      • Delivers EPS of $1.56, representing declines of 33% as reported and 30% on a comparable basis, including $0.72 per share impact from discrete R&D investments
      • Adjusts 2022 revenue guidance to 3% - 5.5% growth as reported and 5.5% - 8% organic. At midpoint, updated outlook reflects expectations for solid second half growth for CAG Diagnostics recurring revenues, similar to recent trends, adjusted for incremental benefits from higher pricing. The low end of the updated outlook incorporates a 2.5% second half organic growth risk estimate related to potential additional impacts from macroeconomic conditions
      • Updated EPS outlook of $7.77 - $8.05 reflects updated revenue outlook, a 50 basis point adjustment to the full year comparable operating margin outlook and $0.08 combined per share impact from updated foreign exchange and interest rate projections

      WESTBROOK, Maine, Aug. 2, 2022 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter results, as well as an update on U.S. companion animal diagnostics trends.

      Second Quarter Results

      The Company reports revenues of $861 million for the second quarter of 2022, a 4% increase as reported and 6.5% organically, driven by Companion Animal Group ("CAG") Diagnostics recurring revenue growth of 4% reported and 7% organic compared to strong prior year performance. Continued solid companion animal sector demand and benefits from IDEXX execution drove premium instrument placements 18% higher than the prior year period, supporting CAG Diagnostics capital instrument revenue growth of 3% as reported and 8% organic. Continued strong momentum in cloud-based software placements supported veterinary software, services and diagnostic imaging systems revenue growth of 27% as reported and 14% organically. Overall revenue gains in the quarter were also supported by Water revenue growth of 5% reported and 9% organic.

      Second quarter earnings per diluted share ("EPS") were $1.56, decreasing 33% as reported and 30% on a comparable basis compared to strong prior year profit levels, reflecting impacts from $80 million of discrete R&D investment in the quarter and operating expense growth related to investments in commercial capabilities. EPS results included $0.06 per share negative impact from currency changes and $0.03 per share in tax benefits from share-based compensation.

      "Building on strong prior year gains, IDEXX drove continued solid organic growth in the second quarter," said Jay Mazelsky, President and Chief Executive Officer. "I am especially pleased with the strong execution of our global teams resulting in record premium instrument placements and cloud- based practice management software adoption. IDEXX innovations have never been more important in helping veterinary clinics manage through capacity challenges and to achieve outstanding care for their patients."

      Companion Animal Diagnostics Trends Update

      Continued growth in demand for companion animal healthcare supported solid gains in CAG diagnostic products and services, compared to strong prior year demand levels. Average diagnostics revenues grew 6% at U.S. veterinary practices on a same-store basis in the second quarter, ahead of 3% growth in overall clinic revenues, reflecting continued expansion of demand for pet healthcare services. U.S. same-store clinical visits at veterinary practices declined 3% in the second quarter compared to prior year period clinical visit growth of 13%, which included benefits from increases in new pet ownership during the COVID-19 pandemic. Growth for pet healthcare including diagnostics has increased significantly from pre-pandemic levels reflecting compound annual growth of 2% in clinical visits and 10% in same-store diagnostics revenues for the U.S. compared to the second quarter of 2019.

      Additional U.S. companion animal practice key metrics are available in the Q2 2022 Earnings Snapshot accessible on the IDEXX website, www.idexx.com/investors.

      Second Quarter Performance Highlights

      Companion Animal Group 

      The Companion Animal Group generated revenue growth of 5% reported and 7% organically for the quarter, supported by CAG Diagnostics recurring revenue growth of 4% on a reported basis and 7% organically. Solid growth was achieved across IDEXX's major modalities, building off high gains in the prior year period. Overall CAG revenue growth included CAG Diagnostics capital instrument revenue growth of 3% reported and 8% organic, reflecting record second quarter premium instrument placements.

      • IDEXX VetLab® consumables generated 4% reported and 8% organic revenue growth, with gains across U.S. and international regions supported by expansion of our global premium instrument installed base, benefits from net price gains and high customer retention levels.
      • Reference laboratory diagnostic and consulting services generated 4% reported and 6% organic revenue growth driven by strong gains in the U.S., offset by flat organic revenue growth in international regions compared to strong prior year levels. Revenue growth reflects benefits from strong customer retention, new business gains and net price improvement.
      • Rapid assay products revenues grew 4% as reported and 6% organically, supported by continued solid volume growth in the U.S. and net price gains.

      Veterinary software, services and diagnostic imaging systems revenues grew 27% as reported and 14% organically, supported by double-digit organic gains in recurring software and digital imaging revenues. Reported growth includes benefits from ezyVet®, acquired during the second quarter of 2021, which continues to show strong momentum in customer gains.

      Water

      Water revenues grew 5% on a reported basis and 9% on an organic basis for the quarter, reflecting solid volume growth across U.S. and international regions and benefits from net price gains.

      Livestock, Poultry and Dairy ("LPD")

      LPD revenues declined 11% as reported and 5% on an organic basis for the quarter, reflecting comparisons to high prior year revenue levels of African Swine Fever and core Swine testing in China. This impact was partially offset by moderate overall organic revenue gains in other areas of the LPD business. Comparisons to high revenue levels for African Swine Fever testing are expected to improve in the second half of 2022.

      Gross Profit and Operating Profit

      Gross profits increased 5% as reported and 7% on a comparable basis. Gross margin of 59.7% increased 50 basis points as reported and was flat on a comparable basis. Benefits from net price gains, lab productivity initiatives and improvement in software service gross margins offset select inflationary effects and impacts from lower LPD revenues.

      Operating margin was 20.8% in the quarter, 1,060 basis points lower than the prior year as reported and 1,050 basis points lower on a comparable basis, driven by year-over-year operating expense growth of 46% as reported and 48% on a comparable basis. Operating expense includes a 35% growth impact and a 900 basis point operating margin impact related to $80 million in discrete R&D investments and reflects increased investments supporting global commercial capabilities, higher travel costs and inflationary impacts.

      2022 Growth and Financial Performance Outlook

      The Company is updating its full year revenue growth outlook to 3% - 5.5% as reported and 5.5% - 8% organically, a reduction in the projected full year revenue growth range of 250 basis points and 200 basis points, respectively. This outlook range includes projected full year CAG Diagnostics recurring revenue growth of 4% - 6% as reported and 6.5% - 9% organic, supported by continued benefits from strong IDEXX execution including additional second half price gains. The updated outlook also incorporates expectations for continued near-term pressure on veterinary clinical visits from factors including constraints on vet clinic capacity, lapping of new patient step-up benefits, as well as additional potential growth impacts related to macroeconomic risk. 

      The Company now projects full year operating margins of 26.4% - 26.9%, reflecting ~50 basis points of net operating margin impact related to updated revenue growth estimates.

      The Company's EPS outlook of $7.77 - $8.05 reflects an adjustment of $0.32 at midpoint, including $0.05 of negative impact from higher projected interest rates and $0.03 of negative impact related to the strengthening U.S. dollar.

      The following table provides the Company's updated outlook for annual key financial metrics in 2022:

      Amounts in millions except per share data and percentages  


      Growth and Financial Performance Outlook


      2022








      Revenue


      $3,305

      -

      $3,385


      Reported growth


      3 %

      -

      5.5 %


      Organic growth


      5.5 %

      -

      8 %


      CAG Diagnostics Recurring Revenue Growth






      Reported growth


      4 %

      -

      6 %


      Organic growth


      6.5 %

      -

      9 %


      Operating Margin


      26.4 %

      -

      26.9 %


      Operating margin expansion


        (260 bps)

      -

      (210 bps)


      Impact of foreign exchange


      ~ 20 bps


      Comparable margin expansion


        (280 bps)

      -

      (230 bps)


      Impact of discrete in-license of technology


      (230 bps)


      EPS


      $7.77

      -

      $8.05


      Reported growth


      (10 %)

      -

      (6 %)


      Comparable growth


      (4 %)

      -

      (1 %)


      Other Key Metrics






      Net interest expense


      $38

      -

      $39


      Share-based compensation tax benefit


      ~ $10


      Share-based compensation tax rate benefit


      ~ 1%


      Effective tax rate


      21.5 %

      -

      22 %


      Share-based compensation EPS impact


      ~ $0.12


      Reduction in average shares outstanding


      ~ 2.0%


      Operating Cash Flow


      90% - 95% of net income


      Free Cash Flow


      65% - 70% of net income


      Capital Expenditures


      ~ $180


      The following table outlines estimates of foreign currency exchange rate impacts, net of foreign currency hedging transactions, and foreign currency exchange rate assumptions reflected in the above financial performance outlook for 2022.

      Estimated Foreign Currency Exchange Rates and Impacts


      2022








      Revenue growth rate impact


      (3.0 %)

      -

      (3.5 %)


      CAG Diagnostics recurring revenue growth rate impact


      ~ (3.5)%


      Operating margin growth impact


      ~ 20 bps


      EPS impact


      (~ $0.21)


      EPS growth impact


      (~ 2.0%)








      Foreign Currency Exchange Rate Assumptions






      In U.S. dollars






      euro


      $1.00


      British pound


      $1.18


      Canadian dollar


      $0.76


      Australian dollar


      $0.67


      Relative to the U.S. dollar






      Japanese yen


      ¥139


      Chinese renminbi


      ¥6.79


      Brazilian real


      R$5.40


      Conference Call and Webcast Information

      IDEXX Laboratories, Inc. will be hosting a conference call today at 8:30 a.m. (EDT) to discuss its second quarter 2022 results and management's outlook. To participate in the conference call, dial 1-866-374-5140 or 1-404-400-0571 and reference pin 28182746. Individuals can access a live webcast of the conference call through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. (EDT) on that day via the same link and will remain available for one year.

      2022 Investor Day

      IDEXX Laboratories, Inc. will host its 2022 Investor Day on Thursday, August 11, 2022 from 8:00 am to approximately 12:00 pm (EDT). A live audio webcast and accompanying slide presentations will be available at www.idexx.com/investors. An archived webcast replay of the event will be available approximately one hour following the event at www.idexx.com/investors. For additional information contact [email protected].

      About IDEXX Laboratories, Inc.

      IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs more than 10,000 people and offers solutions and products to customers in more than 175 countries. For more information about IDEXX, visit www.idexx.com.

      Note Regarding Forward-Looking Statements 

      This earnings release contains statements about the Company's business prospects and estimates of the Company's financial results for future periods that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are included above under "Livestock, Poultry and Dairy ("LPD")", "2022 Growth and Financial Performance Outlook", and elsewhere and can be identified by the use of words such as "expects", "may", "anticipates", "intends", "would", "will", "plans", "believes", "estimates", "projected", "should", and similar words and expressions. Our forward-looking statements include statements relating to our expectations regarding LPD financial performance; revenue growth and EPS outlooks; operating and free cash flow forecast; projected impact of foreign currency exchange rates and interest rates; projected operating margins and expenses and capital expenditures; projected tax, tax rate and EPS benefits from share-based compensation arrangements; and projected effective tax rates, reduction of average shares outstanding and net interest expense. These statements are intended to provide management's expectation of future events as of the date of this earnings release; are based on management's estimates, projections, beliefs and assumptions as of the date of this earnings release; and are not guarantees of future performance. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among other things, the matters described under the headings "Business," "Risk Factors," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 and in the corresponding sections of the Company's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022 and June 30, 2022, as well as those described from time to time in the Company's other filings with the U.S. Securities and Exchange Commission available at www.sec.gov. The Company specifically disclaims any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

      Statement Regarding Non-GAAP Financial Measures

      The following defines terms and conventions and provides reconciliations regarding certain measures used in this earnings release and/or the accompanying earnings conference call that are not required by, or presented in accordance with, generally accepted accounting principles in the United States of America ("GAAP"), otherwise referred to as non-GAAP financial measures. To supplement the Company's consolidated results presented in accordance with GAAP, the Company has disclosed non-GAAP financial measures that exclude or adjust certain items. Management believes these non-GAAP financial measures provide useful supplemental information for its and investors' evaluation of the Company's business performance and liquidity and are useful for period-over-period comparisons of the performance of the Company's business and its liquidity and to the performance and liquidity of our peers. While management believes that these non-GAAP financial measures are useful in evaluating the Company's business, this information should be considered as supplemental in nature and should not be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies.

      Constant currency - Constant currency references are non-GAAP financial measures which exclude the impact of changes in foreign currency exchange rates and are consistent with how management evaluates our performance and comparisons with prior and future periods. We estimated the net impacts of currency on our revenue, gross profit, operating profit, and EPS results by restating results to the average exchange rates or exchange rate assumptions for the comparative period, which includes adjusting for the estimated impacts of foreign currency hedging transactions and certain impacts on our effective tax rates. These estimated currency changes impacted second quarter 2022 results as follows: decreased gross profit growth by 2%, increased gross margin growth by 50 basis points, decreased operating expense growth by 2%, decreased operating profit growth by 2%, decreased operating profit margin growth by 10 basis points, and decreased EPS growth by 2%. Constant currency revenue growth represents the percentage change in revenue during the applicable period, as compared to the prior year period, excluding the impact of changes in foreign currency exchange rates. See the supplementary analysis of results below for revenue percentage change from currency for the three months and six months ended June 30, 2022 and refer to the 2022 Growth and Financial Performance Outlook section of this earnings release for estimated foreign currency exchange rate impacts on 2022 projections and estimates.

      Growth and organic revenue growth - All references to growth and organic growth refer to growth compared to the equivalent prior year period unless specifically noted. Organic revenue growth is a non-GAAP financial measure that excludes the impact of changes in foreign currency exchange rates, certain business acquisitions, and divestitures. Management believes that reporting organic revenue growth provides useful information to investors by facilitating easier comparisons of our revenue performance with prior and future periods and to the performance of our peers. Organic revenue growth should be considered in addition to, and not as a replacement of or a superior measure to, revenue growth reported in accordance with GAAP. See the supplementary analysis of results below for a reconciliation of reported revenue growth to organic revenue growth for the three months and six months ended June 30, 2022. Please refer to the 2022 Growth and Financial Performance Outlook section of this earnings release for estimated full year 2022 organic revenue growth for the Company and CAG Diagnostics recurring revenue. The percentage change in revenue resulting from acquisitions represents revenues during the current year period, limited to the initial 12 months from the date of the acquisition, that are directly attributable to business acquisitions. Revenue from acquisitions is expected to increase projected full year 2022 revenue growth by 50 basis points and to have no impact to projected full year 2022 CAG Diagnostics recurring revenue growth.

      Comparable growth metrics - Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) are non-GAAP financial measures and exclude the impact of changes in foreign currency exchange rates and non-recurring or unusual items (if any). Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts. Management believes that reporting comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) provides useful information to investors because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding key metrics used by management. Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) should be considered in addition to, and not as replacements of or superior measures to, gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin gain reported in accordance with GAAP.

      The reconciliation of these non-GAAP financial measures is as follows:



      Three Months Ended

      Year-over-Year


      Six Months Ended

      Year-over-Year



      June 30


      June 30

      Change


      June 30


      June 30

      Change

      Dollar amounts in thousands


      2022


      2021



      2022


      2021


      Gross Profit (as reported)


      $    514,032


      $    489,308

      5 %


      $ 1,012,785


      $    960,090

      5 %

      Gross margin


      59.7 %


      59.2 %

                   50 bps


      59.7 %


      59.9 %

                   (20) bps

      Less: comparability adjustments











      Change from currency


      (11,768)


      —



      (18,615)


      —


      Comparable gross profit growth


      $    525,800


      $    489,308

      7 %


      $ 1,031,400


      $    960,090

      7 %

      Comparable gross margin and gross margin gain (or growth)


      59.2 %


      59.2 %

      0 bps


      59.3 %


      59.9 %

                   (60) bps












      Operating expenses (as reported)


      $    334,966


      $    230,055

      46 %


      $    585,375


      $    453,215

      29 %

      Less: comparability adjustments











      Change from currency


      $        5,517


      —



      $        8,386


      —


      Comparable operating expense growth


      $    340,483


      $    230,055

      48 %


      $    593,761


      $    453,215

      31 %












      Income from operations (as reported)


      $    179,066


      $    259,253

      (31) %


      $    427,410


      $    506,875

      (16) %

      Operating margin


      20.8 %


      31.4 %

             (1,060) bps


      25.2 %


      31.6 %

                 (640) bps

      Less: comparability adjustments











      Change from currency


      (6,251)


      —



      (10,229)


      —


      Comparable operating profit growth


      $    185,317


      $    259,253

      (29) %


      $    437,639


      $    506,875

      (14) %

      Comparable operating margin and operating margin gain (or growth)


      20.9 %


      31.4 %

             (1,050) bps


      25.2 %


      31.6 %

                 (640) bps

      Amounts presented may not recalculate due to rounding.

      Projected 2022 comparable operating margin expansion outlined in the 2022 Growth and Financial Performance Outlook section of this earnings release reflects projected full year 2022 reported operating margin adjusted for estimated positive year-over-year foreign currency exchange rate change impact of approximately 20 basis points.

      This impact and those described in the constant currency note above reconcile reported gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin gain (including projected 2022 operating margin expansion) to comparable gross profit growth, comparable gross margin gain, comparable operating expense growth, comparable operating profit growth and comparable operating margin gain for the Company.

      Comparable EPS growth -  Comparable EPS growth is a non-GAAP financial measure that represents the percentage change in earnings per share (diluted) ("EPS") for a measurement period, as compared to the prior base period, net of the impact of changes in foreign currency exchange rates from the prior base period and excluding the tax benefits of share-based compensation activity under ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, and non-recurring or unusual items (if any). Management believes comparable EPS growth is a more useful way to measure the Company's business performance than EPS growth because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding a key metric used by management. Comparable EPS growth should be considered in addition to, and not as a replacement of or a superior measure to, EPS growth reported in accordance with GAAP. Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts.

      The reconciliation of this non-GAAP financial measure is as follows:



      Three Months Ended


      Year-over-Year


      Six Months Ended


      Year-over-Year



      June 30


      June 30


      Growth


      June 30


      June 30


      Growth



      2022


      2021




      2022


      2021



      Earnings per share (diluted)


      $             1.56


      $             2.34


      (33) %


      $             3.82


      $             4.69


      (19) %

      Less: comparability adjustments













      Share-based compensation activity


      0.03


      0.07




      0.09


      0.24



      Change from currency


      (0.06)


      —




      (0.09)


      —



      Comparable EPS growth


      1.58


      2.27


      (30) %


      3.83


      4.45


      (14) %

      Amounts presented may not recalculate due to rounding.

      Projected 2022 comparable EPS growth outlined in the 2022 Growth and Financial Performance Outlook section of this earnings release reflects adjustments including estimated positive share-based compensation activity of $0.12 and estimated negative year-over-year foreign currency exchange rate change impact of $0.21.

      These impacts and those described in the constant currency note above reconcile reported EPS growth (including projected 2022 reported EPS growth) to comparable EPS growth for the Company.

      Free cash flow - Free cash flow is a non-GAAP financial measure and means, with respect to a measurement period, the cash generated from operations during that period, reduced by the Company's investments in property and equipment. Management believes free cash flow is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring investments in property and equipment that are required to operate the business. Free cash flow should be considered in addition to, and not as a replacement of or a superior measure to, net cash provided by operating activities. See the supplementary analysis of results below for our calculation of free cash flow for the six months ended June 30, 2022 and 2021. To estimate projected 2022 free cash flow, we have deducted projected purchases of property and equipment (also referred to as capital expenditures) of approximately $180 million. To calculate trailing twelve-month net income to free cash flow ratio for the twelve months ended June 30, 2022, we have deducted purchases of property and equipment of approximately $139 million from net cash provided from operating activities of approximately $578 million, divided by net income of approximately $664 million.

      Debt to Adjusted EBITDA (Leverage Ratios) - Adjusted EBITDA, gross debt, and net debt are non-GAAP financial measures. Adjusted EBITDA is a non-GAAP financial measure of earnings before interest, taxes, depreciation, amortization, non-recurring transaction expenses incurred in connection with acquisitions, share-based compensation expense, and certain other non-cash losses and charges.  Management believes that reporting Adjusted EBITDA, gross debt and net debt in the Debt to Adjusted EBITDA ratios provides supplemental analysis to help investors further evaluate the Company's business performance and available borrowing capacity under the Company's credit facility. Adjusted EBITDA, gross debt, and net debt should be considered in addition to, and not as replacements of or superior measures to, net income or total debt reported in accordance with GAAP. For further information on how Adjusted EBITDA and the Debt to Adjusted EBITDA Ratios are calculated, see the Company's Annual Report on Form 10-K for the year ended December 31, 2021 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.

      IDEXX Laboratories, Inc. and Subsidiaries

      Condensed Consolidated Statement of Operations

      Amounts in thousands except per share data (Unaudited)





      Three Months Ended


      Six Months Ended





      June 30,


      June 30,


      June 30,


      June 30,





      2022


      2021


      2022


      2021

      Revenue:


      Revenue


      $860,546


      $826,142


      $1,697,095


      $1,603,849

      Expenses and Income:


      Cost of revenue


      346,514


      336,834


      684,310


      643,759



      Gross profit


      514,032


      489,308


      1,012,785


      960,090



      Sales and marketing


      130,257


      119,032


      262,549


      233,843



      General and administrative


      81,488


      73,326


      159,437


      144,096



      Research and development


      123,221


      37,697


      163,389


      75,276



      Income from operations


      179,066


      259,253


      427,410


      506,875



      Interest expense, net


      (7,983)


      (7,522)


      (14,836)


      (15,054)



      Income before provision for income taxes


      171,083


      251,731


      412,574


      491,821



      Provision for income taxes


      39,104


      49,125


      86,630


      84,926

      Net Income:


      Net income


      131,979


      202,606


      325,944


      406,895



      Less: Noncontrolling interest in subsidiary's earnings


      —


      24


      —


      56



      Net income attributable to stockholders


      $131,979


      $202,582


      $325,944


      $406,839



      Earnings per share: Basic


      $1.57


      $2.37


      $3.87


      $4.76



      Earnings per share: Diluted


      $1.56


      $2.34


      $3.82


      $4.69



      Shares outstanding: Basic


      83,922


      85,325


      84,164


      85,427



      Shares outstanding: Diluted


      84,858


      86,654


      85,222


      86,794

      IDEXX Laboratories, Inc. and Subsidiaries








      Selected Operating Information (Unaudited)












      Three Months Ended


      Six Months Ended





      June 30,


      June 30,


      June 30,


      June 30,





      2022


      2021

      2022


      2021

      Operating Ratios


      Gross profit


      59.7 %


      59.2 %


      59.7 %


      59.9 %

      (as a percentage of revenue):


      Sales, marketing, general and administrative expense


      24.6 %


      23.3 %


      24.9 %


      23.6 %



      Research and development expense


      14.3 %


      4.6 %


      9.6 %


      4.7 %



      Income from operations1


      20.8 %


      31.4 %


      25.2 %


      31.6 %












      1Amounts presented may not recalculate due to rounding.








      IDEXX Laboratories, Inc. and Subsidiaries

      Segment Information

      Amounts in thousands (Unaudited)














      Three Months Ended





      June 30, 2022


      Percent of
      Revenue


      June 30, 2021


      Percent of
      Revenue








      Revenue:


      CAG


      $784,087




      $745,595





      Water


      39,195




      37,191





      LPD


      29,889




      33,524





      Other


      7,375




      9,832





      Total


      $860,546




      $826,142














      Gross Profit:


      CAG


      $466,254


      59.5 %


      $440,786


      59.1 %



      Water


      27,359


      69.8 %


      25,747


      69.2 %



      LPD


      16,996


      56.9 %


      19,526


      58.2 %



      Other


      3,423


      46.4 %


      3,249


      33.0 %



      Total


      $514,032


      59.7 %


      $489,308


      59.2 %












      Income from
      Operations:


      CAG


      $156,526


      20.0 %


      $234,735


      31.5 %



      Water


      17,920


      45.7 %


      17,228


      46.3 %



      LPD


      3,230


      10.8 %


      6,868


      20.5 %



      Other


      1,390


      18.8 %


      422


      4.3 %



      Total


      $179,066


      20.8 %


      $259,253


      31.4 %



      IDEXX Laboratories, Inc. and Subsidiaries

      Segment Information

      Amounts in thousands (Unaudited)














      Six  Months Ended





      June 30, 2022


      Percent of
      Revenue


      June 30, 2021


      Percent of
      Revenue








      Revenue:


      CAG


      $1,545,271




      $1,438,362





      Water


      75,566




      71,231





      LPD


      60,759




      72,794





      Other


      15,499




      21,462





      Total


      $1,697,095




      $1,603,849














      Gross Profit:


      CAG


      $915,353


      59.2 %


      $853,660


      59.3 %



      Water


      53,096


      70.3 %


      49,212


      69.1 %



      LPD


      36,543


      60.1 %


      46,407


      63.8 %



      Other


      7,793


      50.3 %


      10,811


      50.4 %



      Total


      $1,012,785


      59.7 %


      $960,090


      59.9 %












      Income from
      Operations:


      CAG


      $379,651


      24.6 %


      $447,945


      31.1 %



      Water


      34,574


      45.8 %


      32,000


      44.9 %



      LPD


      9,967


      16.4 %


      20,676


      28.4 %



      Other


      3,218


      20.8 %


      6,254


      29.1 %



      Total


      $427,410


      25.2 %


      $506,875


      31.6 %

      IDEXX Laboratories, Inc. and Subsidiaries

      Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets

      Amounts in thousands (Unaudited)


















      Three Months Ended


























      June 30, 2022


      June 30, 2021


      Dollar
      Change


      Reported
      Revenue
      Growth1


      Percentage
      Change from
      Currency 


      Percentage
      Change from
      Acquisitions


      Organic
      Revenue
      Growth1

      Net Revenue






      CAG


      $784,087


      $745,595


      $38,492


      5.2 %


      (3.3 %)


      1.1 %


      7.3 %

      United States


      532,626


      486,252


      46,374


      9.5 %


      —


      1.5 %


      8.1 %

      International


      251,461


      259,343


      (7,882)


      (3.0 %)


      (9.2 %)


      0.4 %


      5.7 %

      Water


      39,195


      37,191


      2,004


      5.4 %


      (3.5 %)


      —


      8.9 %

      United States


      19,533


      17,747


      1,786


      10.1 %


      —


      —


      10.1 %

      International


      19,662


      19,444


      218


      1.1 %


      (6.7 %)


      —


      7.8 %

      LPD


      29,889


      33,524


      (3,635)


      (10.8 %)


      (5.8 %)


      —


      (5.0 %)

      United States


      3,742


      3,516


      226


      6.5 %


      —


      —


      6.5 %

      International


      26,147


      30,008


      (3,861)


      (12.9 %)


      (6.4 %)


      —


      (6.4 %)

      Other


      7,375


      9,832


      (2,457)


      (25.0 %)


      1.9 %


      —


      (26.9 %)

      Total Company


      $860,546


      $826,142


      $34,404


      4.2 %


      (3.3 %)


      1.0 %


      6.5 %

      United States


      559,825


      515,238


      44,587


      8.7 %


      —


      1.4 %


      7.3 %

      International


      300,721


      310,904


      (10,183)


      (3.3 %)


      (8.6 %)


      0.3 %


      5.0 %




      Three Months Ended




























      June 30, 2022


      June 30, 2021


      Dollar
      Change


      Reported
      Revenue
      Growth1


      Percentage
      Change from

      Currency


      Percentage
      Change from
      Acquisitions


      Organic
      Revenue
      Growth1

      Net CAG Revenue








      CAG Diagnostics recurring revenue:


      $685,413


      $661,300


      $24,113


      3.6 %


      (3.3 %)


      0.2 %


      6.8 %

      IDEXX VetLab consumables


      266,079


      256,352


      9,727


      3.8 %


      (4.1 %)


      —


      7.9 %

      Rapid assay products


      87,481


      83,887


      3,594


      4.3 %


      (1.6 %)


      —


      5.8 %

      Reference laboratory diagnostic and consulting services


      304,130


      293,675


      10,455


      3.6 %


      (3.0 %)


      0.4 %


      6.1 %

      CAG Diagnostics services and accessories


      27,723


      27,386


      337


      1.2 %


      (4.4 %)


      —


      5.7 %

      CAG Diagnostics capital – instruments


      36,227


      35,054


      1,173


      3.3 %


      (4.9 %)


      —


      8.3 %

      Veterinary software, services and diagnostic imaging systems


      62,447


      49,241


      13,206


      26.8 %


      (1.1 %)


      13.8 %


      14.0 %

      Net CAG revenue


      $784,087


      $745,595


      $38,492


      5.2 %


      (3.3 %)


      1.1 %


      7.3 %




      Three Months Ended


























      June 30, 2022


      June 30, 2021


      Dollar
      Change


      Reported
      Revenue
      Growth1


      Percentage
      Change from
      Currency 


      Percentage
      Change from
      Acquisitions


      Organic
      Revenue
      Growth1









      CAG Diagnostics recurring revenue:


      $685,413


      $661,300


      $24,113


      3.6 %


      (3.3 %)


      0.2 %


      6.8 %

      United States


      $460,357


      $427,583


      $32,774


      7.7 %


      —


      0.1 %


      7.6 %

      International


      $225,056


      $233,717


      ($8,661)


      (3.7 %)


      (9.2 %)


      0.4 %


      5.1 %












      1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding.

      IDEXX Laboratories, Inc. and Subsidiaries

      Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets

      Amounts in thousands (Unaudited)


















      Six Months Ended


























      June 30, 2022


      June 30, 2021


      Dollar
      Change


      Reported
      Revenue
      Growth1


      Percentage
      Change from
      Currency 


      Percentage
      Change from
      Acquisitions


      Organic
      Revenue
      Growth1

      Net Revenue








      CAG


      $1,545,271


      $1,438,362


      $106,909


      7.4 %


      (2.6 %)


      1.3 %


      8.7 %

      United States


      1,032,392


      930,662


      101,730


      10.9 %


      —


      1.8 %


      9.1 %

      International


      512,879


      507,700


      5,179


      1.0 %


      (7.3 %)


      0.4 %


      7.9 %

      Water


      75,566


      71,231


      4,335


      6.1 %


      (2.6 %)


      —


      8.7 %

      United States


      37,364


      34,315


      3,049


      8.9 %


      —


      —


      8.9 %

      International


      38,202


      36,916


      1,286


      3.5 %


      (5.0 %)


      —


      8.5 %

      LPD


      60,759


      72,794


      (12,035)


      (16.5 %)


      (3.8 %)


      —


      (12.7 %)

      United States


      7,602


      7,264


      338


      4.7 %


      —


      —


      4.7 %

      International


      53,157


      65,530


      (12,373)


      (18.9 %)


      (4.1 %)


      —


      (14.8 %)

      Other


      15,499


      21,462


      (5,963)


      (27.8 %)


      0.7 %


      —


      (28.5 %)

      Total Company


      $1,697,095


      $1,603,849


      $93,246


      5.8 %


      (2.6 %)


      1.2 %


      7.2 %

      United States


      1,085,731


      987,876


      97,855


      9.9 %


      —


      1.7 %


      8.2 %

      International


      611,364


      615,973


      (4,609)


      (0.7 %)


      (6.7 %)


      0.3 %


      5.6 %




      Six Months Ended




























      June 30, 2022


      June 30, 2021


      Dollar
      Change


      Reported
      Revenue
      Growth1


      Percentage
      Change from

      Currency


      Percentage
      Change from
      Acquisitions


      Organic
      Revenue
      Growth1

      Net CAG Revenue








      CAG Diagnostics recurring revenue:


      $1,350,223


      $1,278,580


      $71,643


      5.6 %


      (2.6 %)


      0.2 %


      8.0 %

      IDEXX VetLab consumables


      533,252


      502,444


      30,808


      6.1 %


      (3.3 %)


      —


      9.5 %

      Rapid assay products


      162,000


      153,498


      8,502


      5.5 %


      (1.3 %)


      —


      6.9 %

      Reference laboratory diagnostic and consulting services


      599,205


      569,456


      29,749


      5.2 %


      (2.3 %)


      0.5 %


      7.0 %

      CAG Diagnostics services and accessories


      55,766


      53,182


      2,584


      4.9 %


      (3.6 %)


      —


      8.4 %

      CAG Diagnostics capital – instruments


      73,224


      66,244


      6,980


      10.5 %


      (4.3 %)


      —


      14.8 %

      Veterinary software, services and diagnostic imaging systems


      121,824


      93,538


      28,286


      30.2 %


      (0.8 %)


      17.3 %


      13.7 %

      Net CAG revenue


      $1,545,271


      $1,438,362


      $106,909


      7.4 %


      (2.6 %)


      1.3 %


      8.7 %


















      Six Months Ended


























      June 30, 2022


      June 30, 2021


      Dollar
      Change


      Reported
      Revenue
      Growth1


      Percentage
      Change from
      Currency 


      Percentage
      Change from
      Acquisitions


      Organic
      Revenue
      Growth1









      CAG Diagnostics recurring revenue:


      $1,350,223


      $1,278,580


      $71,643


      5.6 %


      (2.6 %)


      0.2 %


      8.0 %

      United States


      $892,859


      $820,485


      $72,374


      8.8 %


      —


      0.1 %


      8.7 %

      International


      $457,364


      $458,095


      ($731)


      (0.2 %)


      (7.3 %)


      0.5 %


      6.6 %
















      1See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding.

      IDEXX Laboratories, Inc. and Subsidiaries

      Condensed Consolidated Balance Sheet

      Amounts in thousands (Unaudited)





      June 30,
      2022


      December 31,
      2021






      Assets:


      Current Assets:







      Cash and cash equivalents


      $114,362


      $144,454



      Accounts receivable, net


      412,898


      368,348



      Inventories


      332,565


      269,030



      Other current assets


      183,000


      173,823



      Total current assets


      1,042,825


      955,655



      Property and equipment, net


      594,224


      587,667



      Other long-term assets, net


      970,136


      893,881



      Total assets


      $2,607,185


      $2,437,203

      Liabilities and Stockholders'







      Equity:


      Current Liabilities:







      Accounts payable


      $127,262


      $116,140



      Accrued liabilities


      387,510


      458,909



      Line of credit


      611,000


      73,500



      Current portion of long-term debt


      —


      74,996



      Deferred revenue


      40,775


      40,034



      Total current liabilities


      1,166,547


      763,579



      Long-term debt, net of current portion


      767,995


      775,205



      Other long-term liabilities, net


      215,635


      208,427



      Total long-term liabilities


      983,630


      983,632



      Total stockholders' equity


      457,008


      689,992



      Total liabilities and stockholders' equity


      $2,607,185


      $2,437,203

      IDEXX Laboratories, Inc. and Subsidiaries

      Select Balance Sheet Information (Unaudited)





      June 30,
      2022


      March 31,
      2022


      December 31,
      2021


      September 30,

      2021


      June 30,
      2021

      Selected Balance Sheet Information:


      Days sales outstanding1


      43.2


      42.0


      42.4


      42.7


      42.2



      Inventory turns2


      1.5


      1.6


      2.0


      1.9


      2.1














      1Days sales outstanding represents the average of the accounts receivable balances at the beginning and end of each quarter divided by
      revenue for that quarter, the result of which is then multiplied by 91.25 days.


      2Inventory turns represent inventory-related cost of product revenue for the twelve months preceding each quarter-end divided by the average
      inventory balances at the beginning and end of each quarter.

      IDEXX Laboratories, Inc. and Subsidiaries

      Condensed Consolidated Statement of Cash Flows

      Amounts in thousands (Unaudited)





      Six Months Ended





      June 30, 2022


      June 30, 2021






      Operating:


      Cash Flows from Operating Activities:







      Net income


      $325,944


      $406,895



      Non-cash adjustments to net income


      61,563


      79,002



      Changes in assets and liabilities


      (206,951)


      (127,520)



      Net cash provided by operating activities


      180,556


      358,377

      Investing:


      Cash Flows from Investing Activities:







      Purchases of property and equipment


      (61,924)


      (42,744)



      Acquisition of intangible assets, businesses and equity investment


      (35,000)


      (156,506)



      Net cash used by investing activities


      (96,924)


      (199,250)

      Financing:


      Cash Flows from Financing Activities:







      Borrowings under revolving credit facilities, net


      537,500


      —



      Payment of senior debt


      (75,000)


      —



      Payments for the acquisition-related contingent consideration and holdbacks


      (2,816)


      (1,500)



      Repurchases of common stock


      (573,060)


      (320,787)



      Proceeds from exercises of stock options and employee stock

      purchase plans


      18,379


      27,371



      Shares withheld for statutory tax withholding payments on

      restricted stock


      (10,390)


      (14,952)



      Net cash used by financing activities


      (105,387)


      (309,868)



      Net effect of changes in exchange rates on cash


      (8,337)


      (1,053)



      Net decrease in cash and cash equivalents


      (30,092)


      (151,794)



      Cash and cash equivalents, beginning of period


      144,454


      383,928



      Cash and cash equivalents, end of period


      $114,362


      $232,134

      IDEXX Laboratories, Inc. and Subsidiaries

      Free Cash Flow

      Amounts in thousands except per share data (Unaudited)





      Six Months Ended





      June 30, 2022


      June 30, 2021






      Free Cash Flow:


      Net cash provided by operating activities


      $        180,556


      $        358,377



      Investing cash flows attributable to purchases of property and equipment


      (61,924)


      (42,744)



      Free cash flow1


      $        118,632


      $        315,633








      1See Statements Regarding Non-GAAP Financial Measures, above.

      IDEXX Laboratories, Inc. and Subsidiaries








      Common Stock Repurchases








      Amounts in thousands except per share data (Unaudited)










      Three Months Ended


      Six Months Ended



      June 30, 2022


      June 30, 2021


      June 30, 2022


      June 30, 2021






      Shares repurchased in the open market


      809


      341


      1,311


      618

      Shares acquired through employee surrender for statutory tax withholding


      —


      —


      21


      28

      Total shares repurchased


      809


      341


      1,332


      646










      Cost of shares repurchased in the open market


      $        313,455


      $        188,409


      $        576,238


      $        327,622

      Cost of shares for employee surrenders


      52


      3


      10,390


      14,986

      Total cost of shares


      $        313,507


      $        188,412


      $        586,628


      $        342,608










      Average cost per share – open market repurchases


      $          387.78


      $          552.08


      $          439.63


      $          529.45

      Average cost per share – employee surrenders


      $          369.63


      $          550.59


      $          504.60


      $          544.08

      Average cost per share – total


      $          387.78


      $          552.08


      $          440.63


      $          530.07

      Contact: John Ravis, Investor Relations, 1-207-556-8155

      SOURCE IDEXX Laboratories, Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.